Glioblastoma - bevacizumab [ID80]
In development [GID-TAG413] Expected publication date: TBC
Search results
670 results
-
-
Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) ID622
In development [GID-TAG360] Expected publication date: TBC
-
Lymphoma (non Hodgkin's, peripheral T-cell) - pralatrexate [ID368]
In development [GID-TAG424] Expected publication date: TBC
-
Multiple myeloma - bortezomib (consolidation therapy) [ID529]
In development [GID-TAG320] Expected publication date: TBC
-
Multiple myeloma (one prior therapy) - vorinostat (with bortezomib) [ID501]
In development [GID-TAG435] Expected publication date: TBC
-
Generalised anxiety disorder - quetiapine [ID347]
In development [GID-TAG421] Expected publication date: TBC
-
Pancreatic cancer - capecitabine [ID389]
In development [GID-TAG394] Expected publication date: TBC
-
Melanoma (advanced and metastatic) - temozolomide [ID316]
In development [GID-TAG401] Expected publication date: TBC
-
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]
In development [GID-TAG406] Expected publication date: TBC
-
Constipation (opioid induced) - lubiprostone [ID646]
In development [GID-TAG367] Expected publication date: 01 October 2014
-
Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]
Proposed [GID-TA10668] Expected publication date: TBC
-
Epilepsies in children, young people and adults
In development [GID-NG10112] Expected publication date: 16 November 2021
-
Eryaspase with chemotherapy for previously treated advanced or metastatic pancreatic cancer [ID3781]
Proposed [GID-TA10637] Expected publication date: TBC
-
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]
Proposed [GID-TA10638] Expected publication date: TBC
-
Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545
In development [GID-TA10418] Expected publication date: TBC
-
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]
Proposed [GID-TA10667] Expected publication date: TBC
-
Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma [ID1629]
In development [GID-TA10576] Expected publication date: TBC
-
Epilepsies in adults: diagnosis and management update (Please see Epilepsies in children, young people and adults)
In development [GID-NG10110] Expected publication date: TBC
-
Short bowel syndrome - teduglutide [ID885]
In development [GID-TA10048] Expected publication date: TBC
-
TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices [ID1440]
In development [GID-TA10370] Expected publication date: TBC
-
Baloxavir marboxil for treating influenza [ID1537]
In development [GID-TA10559] Expected publication date: TBC
-
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders [ID1319]
In development [GID-TA10544] Expected publication date: TBC
-
Apalutamide for treating prostate cancer [ID1534]
In development [GID-TA10423] Expected publication date: 26 May 2021
-
Baricitinib for treating moderate to severe atopic dermatitis [ID1622]
In development [GID-TA10562] Expected publication date: 03 March 2021
-
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma [ID1620]
In development [GID-TA10491] Expected publication date: TBC
-
Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]
In development [GID-TA10570] Expected publication date: 17 November 2021
-
Fostamatinib for treating persistent or chronic immune thrombocytopenia [ID1087]
In development [GID-TA10387] Expected publication date: TBC
-
Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously treated EGFR-positive metastatic non-small-cell lung cancer [ID3873]
Proposed [GID-TA10766] Expected publication date: TBC
-
Pevonedistat with azacitidine for untreated myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia [ID3877]
Proposed [GID-TA10767] Expected publication date: TBC
-
Bintrafusp alfa for treating advanced biliary tract cancer after platinum-based chemotherapy [ID3874]
Proposed [GID-TA10768] Expected publication date: TBC
-
Pralsetinib for treating RET-positive advanced non-small-cell lung cancer after platinum-based chemotherapy [ID3875]
Proposed [GID-TA10770] Expected publication date: TBC
-
Tofacitinib for treating active ankylosing spondylitis [ID3865]
Proposed [GID-TA10771] Expected publication date: TBC
-
Foscarbidopa–foslevodopa for treating motor fluctuations in Parkinson's disease [ID3876]
Proposed [GID-TA10772] Expected publication date: TBC
-
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]
Proposed [GID-TA10773] Expected publication date: TBC
-
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]
Proposed [GID-TA10774] Expected publication date: TBC
-
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]
Proposed [GID-TA10775] Expected publication date: TBC
-
Andexanet alfa for reversing anticoagulation [ID1101]
In development [GID-TA10440] Expected publication date: 14 April 2021
-
Stroke rehabilitation in adults
In development [GID-NG10175] Expected publication date: 14 December 2022
-
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]
Proposed [GID-TA10776] Expected publication date: TBC
-
Atezolizumab with chemotherapy for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer [ID3894]
Proposed [GID-TA10777] Expected publication date: TBC
-
Lisocabtagene maraleucel (Liso-cel) for transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas [ID3887]
Proposed [GID-TA10778] Expected publication date: TBC
-
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]
Proposed [GID-TA10779] Expected publication date: TBC
-
Midostaurin for treating advanced systemic mastocytosis ID1573
In development [GID-TA10503] Expected publication date: TBC
-
Postnatal care
In development [GID-NG10070] Expected publication date: 07 April 2021
-
Ectopic pregnancy and miscarriage: diagnosis and initial management (update)
In development [GID-NG10173] Expected publication date: TBC
-
Rehabilitation for Chronic Neurological Disorders Including Traumatic Brain Injury
In development [GID-NG10181] Expected publication date: TBC
-
Olaparib with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer [ID1652]
In development [GID-TA10526] Expected publication date: TBC
-
Head injury: assessment and early management
In development [GID-NG10164] Expected publication date: 11 May 2022
-
Lenvatinib with everolimus or pembrolizumab for untreated advanced renal cell carcinoma [ID3760]
In development [GID-TA10629] Expected publication date: TBC
-
Galcanezumab for preventing cluster headache [ID1212]
In development [GID-TA10425] Expected publication date: 24 February 2021